China Human Vaccine Industry Report, 2017-2021 2021 July 2017
STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs. METHODOLOGY Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. REPORT OBJECTIVES Subsequently, telephone interviews or email correspondence To establish a comprehensive, factual, annually updated d and cost- was conducted with marketing executives etc. Other sources effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts. To assist potential market entrants in evaluating prospective acquisition and joint venture candidates. To complement the organizations internal competitor information gathering efforts with strategic analysis, data interpretation and insight. To suggest for concerned investors in line with the current development of this industry as well as the development tendency. included related magazines, academics, and consulting companies. INFORMATION SOURCES The primary information sources include Company Reports, and National Bureau of Statistics of China etc. To help company to succeed in a competitive market, and Copyright 2012 ResearchInChina understand the size and growth rate of any opportunity.
Abstract The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined. Affected by the illegal vaccine case in Mar 2016 in Shandong, the country s lot release volume of human vaccines came to 553.6million doses through the year 2016, down 3.8% over the previous year. The lot release volume of ten vaccines (Hepatitis B vaccine, Diphtheria, Tetanus and acellular Pertussis combined vaccine (adsorbed), rabies vaccine, Japanese encephalitis vaccine, poliomyelitis vaccine, meningococcal vaccine, measles and rubella combined attenuated live vaccine, MMR combined attenuated live vaccine, influenza vaccine, and Hepatitis A Vaccine) was relatively higher, totaling 467.2 million doses, 84.4% of the country s total, a year-on-year 1.4% drop. 2. The industry was highly concentrated. The Chinese human vaccine market had been highly concentrated, primarily dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, and Changchun Institute of Biological Products under China National Biotec Group Company Limited. In 2016, China National Biotec Group accounted for 52.6% of the country s lot release volume of human vaccines, compared with a small fraction of market share for Liaoning Chengda Biotechnology, Changsheng Bio-technology, Shenzhen Kangtai Biological Products, Chongqing Zhifei Biological Products, Beijing Minhai Biotechnology, Walvax Biotechnology, Changchun BCHT Biotechnology, Hualan Biological Engineering, Zhejiang Tianyuan Bio-Pharmaceutical, and Sinovac Biotech. 3. Vaccine enterprises scaled up R&D efforts. Major Chinese vaccine enterprises have intensified their efforts for R&D in order to enhance overall competitiveness in recent years. Walvax Biotechnology has started HPV-2 industrialization project and is expected to launch the product in 2019, and meanwhile has put its 13-valent pneumococcal combined vaccine in phase III clinical trial and is predicted to bring the product to the market in 2018 or 2019. Launching of new vaccines will make the company more competitive. Copyright 2012ResearchInChina
Copyright 2012ResearchInChina
4. Two-child policy, population aging, and new vaccines were drivers of the industry. Along with full implementation of the two-child policy in Oct 2015, the country s newborns increased sharply py to 17.86 million in 2016 and will remain above 18 million each year over the next five years. Meanwhile, the population aged 60 and over reached 230.9 million by the end of 2016 and is expected to hit 245.3 million by 2021. In addition, some domestic enterprises have set about developing new vaccines like HPV vaccine and 13-valent pneumococcal vaccine which are expected to be available on the market in 2018 or 2019. Pushed by the two-child policy, population aging, and launching of new vaccines, the vaccine industry in China will grow rapidly with an estimated market size of up to RMB31.2 billion in 2021. China Human Vaccine Industry Report, 2017-2021 highlights the following: Human vaccine industry in China (operating environment, status quo, market demand, market size, circulation channel, import & export, competitive landscape, development trends, etc.); Analysis on Chinese human vaccine market segments(like Hepatitis B Vaccine, Meningococcal Vaccine, Hepatitis A vaccine, Influenza Vaccine, Hib Vaccine, Rabies Vaccine, Varicella Vaccine, Pneumococcal Vaccines, DTP Vaccine, Poliomyelitis Vaccine, Hepatitis E Vaccine), including market demand, lot release volume, competitive landscape, etc.; 19 local vaccine enterprises (operation, gross margin, major customers, R&D and investment, development and forecast, etc.). Copyright 2012ResearchInChina
Table of contents 1. Overview of Vaccine Industry 1.1 Definition & Classification 1.2 Industry Chain 2. China Human Vaccine Industry Development Analysis 2.1 Operating Environment 2.1.1 International Market 2.1.2 Policy Environment 2.1.3 Biopharmaceutical Market 2.2 Status Quo 2.3 Supply & Demand 2.4 Market Size 2.5 Circulation Channel 2.6 Import & Export 2.6.1 Import 2.6.2 Export 2.6.3 Average Price 2.7 Competition Pattern 2.8 Development Trend 2.8.1 Vaccine for Cervical Cancer Prevention is expected to be launched in China 2.8.2 Domestic Pneumococcal 13-valent Conjugate Vaccine is Expected to be launched 2.8.3 Two-child Policy Favorable to Industry Development 2.8.4 Aging gpopulation p propel p industry development to some extent 2.8.5 Industry scale rises stably 3. Human Vaccine Market Segments in China 3.1 Hepatitis B Vaccine 311S 3.1.1 Supply &D Demand 3.1.2 Lot Release Volume 3.1.3 Competition Pattern 3.2 Meningococcal Vaccine 3.2.1 Supply & Demand 3.2.2 Lot Release Volume 3.2.3 Competition Pattern 3.3 Hepatitis A Vaccine 3.3.1 Supply & Demand 3.3.23 Lot Release Volume 3.3.3 Competition Pattern 3.4 Influenza Vaccine 3.4.1 Supply & Demand 3.4.2 Lot Release Volume 343C 3.4.3 Competition Pattern 3.5 Hib Vaccine 3.5.1 Supply & Demand 3.5.2 Lot Release Volume 3.5.3 Competition Pattern 3.5.4 Market Forecast 3.6 Human Rabies Vaccine 3.6.1 Supply & Demand 3.6.2 Lot Release Volume 3.6.3 Competition Pattern 3.7 Varicella Vaccine 3.7.1 Supply & Demand 3.7.2 Lot Release Volume 3.7.3 Competition Pattern 38P 3.8 Pneumococcal lvaccines 3.8.1 Supply & Demand 3.8.2 Lot Release Volume 3.8.3 Competition Pattern 3.9 DTP Vaccine 3.9.1 Supply & Demand 3.9.2 Lot Release Volume 3.9.3 Competition Pattern 3.10 Poliomyelitis Vaccine 3.10.1 1 Supply & Demand 3.10.2 Lot Release Volume 3.10.3 Competition Pattern 3.11 Hepatitis E Vaccine 3.11.1 Supply & Demand 3112L 3.11.2 Lot trelease Volume 3.11.3 Competition Pattern 4. Major Vaccine Manufacturers in China 4.1 China National Biotec Group 4.1.1 Profile 4.1.2 Beijing Tiantan Biological Products Co., Ltd 4.1.3 Chengdu Institute of Biological Products 4.1.4 Shanghai Institute of Biological Products 4.1.5 Wuhan Institute of Biological Products 4.1.6 Lanzhou Institute of Biological Products 4.1.7 Changchun Institute of Biological Products
Table of contents 4.2 Beijing Tiantan Biological Products Co., Ltd. 4.2.1 Profile 422O 4.2.2 Operation 4.2.3 Revenue Structure 4.2.4 Gross Margin 4.2.5 R&D Cost and Investment 4.2.6 Clients 4.2.7 Vaccine Business 4.2.8 Development and Prospects 4.3 Hualan Biological Engineering Inc. 4.3.1 Profile 432Operation 4.3.2 4.3.3 Revenue Structure 4.3.4 R&D Cost and Investment n 4.3.5 Clients 4.3.6 Vaccine Business 437D 4.3.7 Development and dprospects 4.4 Chongqing Zhifei Biological Products Co., Ltd. 4.4.1 Profile 4.4.2 Operation 4.4.3 Revenue Structure 4.4.4 Gross Margin 4.4.5 Major Clients 4.4.6 R&D Cost and Investment 4.4.7 Development and Prospects 4.5 Walvax Biotechnology Co, Ltd. 4.5.1 Profile 4.5.2 Operation 4.5.3 Revenue Structure 4.5.4 Gross Margin 455M 4.5.5 Major Clients 4.5.6 R&D Cost and Investment 4.5.7 Vaccine Business 4.5.8 Development and Prospects 4.6 Liaoning Cheng Da Co., Ltd. 4.6.1 Profile 4.6.2 Operation 4.6.3 Revenue Structure 4.6.4 Gross Margin 465Clients 4.6.5 4.6.6 R&D Cost and Investment 4.6.7 Development and Prospects 4.7 Shenzhen Kangtai Biological Products Co., Ltd. 4.7.1 Profile 472O 4.7.2 Operation 4.7.3 Revenue Structure 4.7.4 Gross Margin 4.7.5 Clients 4.7.6 R&D Cost and Investment 4.7.7 Development and Prospects 4.8 Changchun Changsheng Life Sciences Limited 4.8.1 Profile 4.8.2 Operation 4.8.3 Revenue Structure 4.8.4 R&D Cost and Investment 4.8.5 Development and Prospects 4.9 Sinovac Biotech Ltd. 4.9.1 Profile 492O 4.9.2 Operation 4.9.3 Revenue Structure 4.9.4 Sinovac Biotech (Beijing) 4.10 Changchun BCHT Biotechnology Co. Ltd. 4.10.1 Profile 4.10.2 Operation 4.10.3 Development Dynamics 4.11 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. 4.11.1 Profile 4.11.2 Operation 4.12 Dalian Hissen Bio-Pharm Co., Ltd. 4.12.1 Profile 4.13 NCPC GeneTech Biotechnology Development 4.13.1 Profile 4132O 4.13.2 Operation 4.14 Dalian Aleph Biomedical Co., Ltd. 4.14.1 Profile 4.14.2 Development Dynamics 4.15 Beijing Minhai Biotechnology Co., Ltd. 4.15.1 Profile 4.15.2 Operation 4.16 Shenzhen Sanofi Pasteur Biological Products 4.17 Other Enterprises 4.17.1 Jiangsu SimcereVaxtec Bio-pharmaceutical 4.17.2 Xiamen Innovax Biotech CO., LTD. 4.17.3 Convac Biotechnology Co., Ltd.
Classification of Vaccines Vaccine Industry Chain Global Human Vaccine Market Size, 2010-2016 Global Human Vaccine Market Size, 2016-2021E Revenue of Top 5 Vaccine Companies, 2008-2016 Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2015 Policies in Vaccine Industry, 2016-2017 Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2016 Gross Industrial Output Value of China Biopharmaceutical Industry, 2016-2021E EPI Human Vaccine Varieties in China Lot Release Volume of Human Vaccine in China, 2013-2017 Top10 Human Vaccines by Lot Release Volume in China, 2015-2016 Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, 2016 Provinces Completing Online Publicity of Vaccine Procurement in China by the End of Mar 2017 China Human Vaccine Market Size, 2010-2016 2016 Import Volume and Value of Human Vaccine in China, 2010-2017 China s Human Vaccine Import Volume and Value by Country, 2016 Export Volume and Value of Human Vaccine in China, 2010-2017 Top 10 Countries/Regions of China Human Vaccine Export Average Unit Export/Import Price of Human Vaccine in China, 2010-2017 Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2016 Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2017H1 Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2015-2017 Lot Release Volume of Vaccines in China by Enterprise, 2016 Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2016 Selected Charts
Market Share of Human Vaccine Industry in China by Enterprise, 2016 R&D Projects and Progress of Major Vaccine Enterprises in China by the End of 2016 Morbidity of Cervical Cancer Worldwide Global HPV Vaccines Global HPV Vaccine Market Size, 2006-2015 Shanghai Zerun Biotechnology s Progress in R&D of HPV Vaccine China s Newborns, 2015-2021E Population Aged 60 and Over in China, 2009-2021E Chinese Vaccine Market Size, 2016-2021E Hepatitis B Morbidity and Mortality in China, 2013-2016 Lot Release Volume of Hepatitis B Vaccine in China, 2015-20172017 Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2015-2017 Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2015-2017 Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2015-2017 Meningitis Morbidity and Mortality in China, 2013-2016 Meningococcal Vaccines Lot Release Volume in China, 2015-2017 Meningococcal Vaccines Lot Release Volume in China by Type, 2015-2017 Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2015-2017 Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2015-2017 Hepatitis A Morbidity and Mortality in China, 2013-2016 Lot Release Volume of Hepatitis A Vaccine in China, 2015-2017 Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2015-2017 Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2015-2017 H7N9 Influenza Morbidity and Mortality in China, 2013-2016 Lot Release Volume of Influenza Vaccine in China, 2015-2016 Selected Charts
Lot Release Volume of Major Influenza Vaccine Companies in China, 2015-2016 Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2015-2016 2016 Lot Release Volume of Hib Vaccine in China, 2015-2017 Lot Release Volume of Major Hib Vaccine Companies in China, 2015-2017 Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2015-2017 Rabies Morbidity and Mortality in China, 2013-2016 Lot Release Volume of Human Rabies Vaccine in China, 2015-2017 Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2015-2017 Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2015-2017 Lot Release Volume of Varicella Vaccine in China, 2015-2017 Lot Release Volume of Major Varicella Vaccine Companies in China, 2015-2017 Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2015-2017 Lot Release Volume of Pneumococcal Vaccines in China, 2015-2017 Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2015-2017 Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2015-20172017 Pertussis Morbidity and Mortality in China, 2012-2016 Neonatal Tetanus Morbidity and Mortality in China, 2012-2016 Lot Release Volume of DTP Vaccine in China, 2015-2017 Lot Release Volume of Major DTP Vaccine Companies in China, 2015-2017 Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2015-2017 Poliomyelitis Morbidity and Mortality in China, 2011-2016 Lot Release Volume of Poliomyelitis Vaccine in China, 2015-2017 Lot Release Volume of Major Poliomyelitis Vaccine Companies in China, 2015-2017 Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2015-2017 Hepatitis E Morbidity and Mortality in China, 2012-2016 Selected Charts
Lot Release Volume of Hepatitis E Vaccine in China, 2015-2016 Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2015-2016 Vaccine Varieties of Chengdu Institute of Biological Products Vaccine Lot Release Volume Breakdown of Chengdu Institute of Biological Products by Product, 2015-2017 Vaccine Varieties of Shanghai Institute of Biological Products Operation of Shanghai Institute of Biological Products, 2013-2016 Vaccine Lot Release Volume Breakdown of Shanghai Institute of Biological Products by Product, 2015-2017 Vaccine Lot Release Volume Breakdown of Wuhan Institute of Biological Products by Product, 2015-2017 Vaccine Lot Release Volume Breakdown of Lanzhou Institute of Biological Products by Product, 2015-2017 Vaccine Lot Release Volume Breakdown of Changchun Institute of Biological Products by Product, 2015-2017 Revenue and Net Income of Beijing Tiantan Biological i l Products, 2013-2017 2017 Revenue Breakdown of Beijing Tiantan Biological Products by Product, 2013-2016 Revenue Structure of Beijing Tiantan Biological Products by Product, 2013-2016 Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2013-2016 Revenue Structure of Beijing Tiantan Biological Products by Region, 2013-2016 2016 Gross Margin of Beijing Tiantan Biological Products by Product, 2013-2016 R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2013-2016 Main R&D Projects of Beijing Tiantan Biological Products as of the end of 2016 Beijing Tiantan Biological Products Revenue from Top5 Customers and % of Total Revenue, 2012-2016 Vaccine Revenue and Percentage of Beijing Tiantan Biological Products, 2013-2016 Output & Sales Volume of Major Vaccine Products of Beijing Tiantan Biological Products, 2016 Bidding Status of Beijing Tiantan Biological Products in Centralized Procurement Bidding, 2016 Revenue and Operating Income of Beijing Tiantan Biological Products, 2016-2021E Revenue and Net Income of Hualan Biological Engineering, 2013-2017 Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2016 Selected Charts
Revenue Structure of Hualan Biological Engineering by Sector, 2013-2016 R&D Costs and % of Total Revenue of Hualan Biological Engineering, g, 2013-2016 Hualan Biological Engineering s Revenue from Top5 Customers and % of Total Revenue, 2013-2016 Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2016 Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2016 Major Products and Application of Chongqing Zhifei Biological Products Major Subsidiaries of Chongqing Zhifei Biological Products Revenue and Net Income of Chongqing Zhifei Biological Products, 2012-2017 Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2016 Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2016 R B kd f Ch i Zhif i Bi l i l P d t b R i 2014 2016 Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2014-2016 Gross Margin of Chongqing Zhifei Biological Products by Product, 2013-2016 Chongqing Zhifei Biological Products Revenue from Top5 Customers and % of Total Revenue, 2011-2016 R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2011-2016 Projects under Registration Process of Chongqing Zhifei Biological Products, 2016 Progress of Preclinical Projects of Chongqing Zhifei Biological Products by the end of 2016 Revenue and Operating Income of Chongqing Zhifei Biological Products, 2016-2021E Revenue and Net Income of Walvax Biotechnology, 2013-2017 Revenue Breakdown of Walvax Biotechnology by Product, 2014-2016 Revenue Breakdown of Walvax Biotechnology by Region, 2014-2016 Gross Margin of Walvax Biotechnology by Product, 2013-2016 Walvax Biotechnology s Revenue from Top5 Customers and % of Total Revenue, 2015-2016 R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2016 Progress of Products under Registration Declaration of Walvax Biotechnology as of the end of Mar.2017 Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2016 Selected Charts
Lot Release Volume of Walvax Biotechnology, 2014-2016 Revenue and Operating Income of Walvax Biotechnology, 2016-2021E 2021E Revenue and Net Income of Liaoning Chengda, 2013-2016 Revenue Breakdown of Liaoning Chengda by Sector, 2013-2016 Revenue Structure of Liaoning Chengda by Sector, 2013-2016 Gross Margin of Liaoning Chengda, 2013-2016 Liaoning Chengda s Revenue from Top5 Customers and % of Total Revenue, 2015-2016 R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2016 Revenue and Net Income of Liaoning Chengda Biotechnology, 2016-2021E Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2016 Revenue and Net Income of Shenzhen Kangtai Biological Products, 2013-2017 Revenue Breakdown of Shenzhen Kangtai Biological Products by Product, 2015-2016 Lot Release Volume and Percentage of Shenzhen Kangtai Biological Products, 2015-2016 Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2016 Gross Margin of Shenzhen Kangtai Biological Products, 2013-20162016 Shenzhen Kangtai Biological Products Revenue from Top5 Customers and % of Total Revenue, 2014-2016 R&D Costs and % of Total Revenue of Shenzhen Kangtai Biological Products, 2013-2016 IPO Fund-Rasing Projects of Shenzhen Kangtai Biological Products Revenue and Net Income of Shenzhen Kangtai Biological Products, 2016-2021E Equity Structure of Changchun Changsheng Life Sciences Revenue and Net Income of Changchun Changsheng Life Sciences, 2014-2017 Output & Sales Volume, Inventory of Changchun Changsheng Life Sciences, 2014-2016 Revenue Breakdown of Changchun Changsheng Life Sciences by Product,2014-2016 Revenue Structure of Changchun Changsheng Life Sciences by Product, 2014-2016 Revenue Breakdown of Changchun Changsheng Life Sciences by Region, 2014-2016 Selected Charts
Selected Charts Revenue Structure of Changchun Changsheng Life Sciences by Region, 2014-2016 R&D Costs and % of Total Revenue of Changchun Changsheng Life Sciences, 2014-2016 2016 Progress of Projects under R&D of Changchun Changsheng Life Sciences as of the end of 2016 Revenue and Net Income of Changchun Changsheng Life Sciences, 2016-2021E Revenue and Net Income of Sinovac Biotech, 2013-2016 Revenue Breakdown of Sinovac Biotech by Product, 2013-2016 Financial Indices of Sinovac Biotech, 2015-2016 Financial Indices of Changchun BCHT Biotechnology, 2014-2016 Equity Structure of Zhejiang Tianyuan Bio-Pharmaceutical Vaccine Products of Zhejiang Tianyuan Bio-Pharmaceutical Revenue and Net Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2016 Financial Indices of Zhejiang Tianyuan Bio-Pharmaceutical, 2014-2016 Equity Structure of Dalian Aleph Biomedical Financial Indices of Beijing Minhai Biotechnology, 2015-2016 Total Assets and Revenue of Shenzhen Sanofi Pasteur Biological Products, 2016 Development Course of Xiamen Innovax Biotech
How to Buy You can place your order in the following alternative ways: 1.Order online at www.researchinchina.com 2.Fax order sheet to us at fax number:+86 10 82601570 3. Email your order to: report@researchinchina.com 4. Phone us at +86 10 82600828/ 82601561 Choose type of format PDF (Single user license)..2,800 USD Hard copy.. 3,000 USD PDF (Enterprisewide license)... 4,400 USD Party A: Name: Address: Contact Person: E-mail: Tel Fax Party B: Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina) Address: Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Contact Liao Yan Phone: 86-10-82600828 Person: E-mail: report@researchinchina.com Fax: 86-10-82601570 Bank details: Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,landianchang,haidian District,Beijing Bank Account No #: 110060668012015061217 Routing No # : 332906 Bank SWIFT Code: COMMCNSHBJG Reports will be dispatched immediately once full payment has been received. Payment may be made by wire transfer or credit card via PayPal. Title Format Cost Total
About ResearchInChina RICDB service ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research. Our Major Activities Multi-users market reports Database-RICDB Custom Research Company Search RICDB (http://www.researchinchina.com/data/database.html com/data/database html ), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map. After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free. After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com For any problems, please contact our service team at: